(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 ...
The Swiss pharma is paying $12 billion for Avidity Biosciences and its three late-stage antibody oligonucleotide conjugates.
Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in ...
The drugmaker’s net profit rose as it weathered generic competition for blockbuster medicines, but shares still fell.
Secondary endpoints “indicate symptom reduction and patient benefit beyond improvement in disease activity,” according to ...
Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in ...
Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal ...
Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter, dragging the Swiss company's ...
The findings position Fabhalta to secure a standard approval in IgA nephropathy — a crowded area of drug research — at a time when newer types of medicines are quickly advancing.
Swiss drugmaker Novartis is exploring options to add more medicines to its direct-to-patient platform that is expected to ...
Novartis is buying Avidity Biosciences for $12 billion, picking up RNA-based medicines for neuromuscular diseases as it seeks ...
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren’s disease, the second most prevalent rheumatic autoimmune disease 2, at a late-breaker presentation during the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback